Graves病低钾血症与HLA-DQA1等位基因的关联  

Association between Hypokalemia in Graves’Disease and Polymorphism of HLA-DQA1 Alleles

作　　者：袁梦华[1] 李梅[1] 邱明才[1] 张鹏[1] 谷奕[1] 

机构地区：[1]天津医科大学总医院内分泌科,300052

出　　处：《天津医药》2009年第2期98-100,I0002,共4页Tianjin Medical Journal

基　　金：天津市教委科技发展基金资助项目(项目编号:020201)

摘　　要：目的:探讨天津地区汉族人Graves病(GD)低钾血症与HLA-DQA1等位基因多态性的关系。方法:采用PCR-限制性酶切片段长度多态性分析法(RFLP)测定GD患者及正常对照者的HLA-DQA1等位基因型,计算并比较GD和正常对照组的基因型频率;GD中周期性麻痹患者、非周期性麻痹低血钾患者和正常血钾患者的基因型频率。结果:GD患者HLA-DQA1*0301基因频率明显高于正常对照组(RR=1.577,P<0.05);而HLA-DQA1*0201和HLA-DQA1*0401基因频率明显低于正常对照组(RR=0.395,P<0.05;RR=0.113,P<0.01)。GD中周期性麻痹患者、非周期性麻痹低血钾患者与正常血钾患者相比,HLA-DQA1等位基因的基因频率差异无统计学意义(P>0.05)。结论:HLA-DQA1*0301可能是天津地区汉族人群GD甲亢的易感基因,而HLA-DQA1*0201和HLA-DQA1*0401可能是天津地区汉族人GD甲亢的保护基因;但未发现GD低钾血症与HLA-DQA1基因有关。Objective： To investigate the relationship between HLA-DQA1 polymorphism and hypokalemia in patients with Graves＇disease in Han Group in Tianjin area. Methods： The allelic types of HLA-DQA1 were evaluated by polymerase chain reaction fragment length polymorphism （PCR-RFLP）. The allelic gene frequencies were compared between patients with Graves＇ disease and normal controls, and also compared between patients with hypokalemia （including thyrotoxic periodic paralysis and non-thyrotoxic periodic paralysis） and those without it in Graves＇ disease. Results： The allelic gene frequencies of HLA-DQA 1^＊0301 in patients with Graves＇ disease were significantly increased as compared with the controls （RR=1.577, P 〈 0.05）, while those of HLA-DQA1^＊0201 and DQA 1^＊0401 were obviously decreased （RR=0.395, P 〈 0.05 ;RR=0.113, P 〈 0.01） in relation to controls. In Graves＇ disease, differences of allelic gene frequencies were not found between patients with hypokalemia and those without it. Conclusion： HLA-DQA1 ^＊0301 may be the susceptibility gene for Graves＇ disease in Tianjin Han nationality. HLA-DQA1^＊0201 and DQA1^＊0401 may be the protective gene for Graves＇ disease. The correlation between hypokalemia and HLA-DQA 1 was not found.

关 键 词：格雷夫斯病 低钾血症 HLA—DQ抗原 等位基因 低钾性周期性麻痹 

分 类 号：R739.63[医药卫生—肿瘤] R392.13[医药卫生—临床医学]